EPAS1 and neoplasm: Besides lipid metabolism, HIF-2α inhibition disturbs the glycolytic and other anabolic pathways critical for tumor adaptation to hypoxia, causing downregulation of VEGFA, CCND1, and SLC2A1 (39).